open access

Vol 81, No 1 (2013)
REVIEWS
Published online: 2012-12-13
Submitted: 2013-02-22
Get Citation

Treatment of non-small cell lung cancer — where we are?

Janusz Milanowski, Katarzyna Szmygin-Milanowska
Pneumonol Alergol Pol 2013;81(1):55-62.

open access

Vol 81, No 1 (2013)
REVIEWS
Published online: 2012-12-13
Submitted: 2013-02-22

Abstract

Lung cancer is the most common cancer in Poland and in the world, unfortunately diagnosed too late, and combined with a very poor prognosis. For most patients with NSCLC the only possibility of treatment is palliative therapy, including chemotherapy and, in the recent years, molecular targeted therapy. In first-line treatment, cisplatine-based “doublets” are most effective, and in second-line, pemetreksed and docetaxel are used. Recently, maintenance chemotherapy has been introduced. Although standard chemotherapy improves the quality of life in the patients with advanced NSCLC, due to significant toxicity such treatment should be applied only in patients in good performance status. The introduction of targeted therapy, based on the molecular profile of the patient has allowed the management to be personalized, which may result in more effective treatment and may be safer for the patient.

Abstract

Lung cancer is the most common cancer in Poland and in the world, unfortunately diagnosed too late, and combined with a very poor prognosis. For most patients with NSCLC the only possibility of treatment is palliative therapy, including chemotherapy and, in the recent years, molecular targeted therapy. In first-line treatment, cisplatine-based “doublets” are most effective, and in second-line, pemetreksed and docetaxel are used. Recently, maintenance chemotherapy has been introduced. Although standard chemotherapy improves the quality of life in the patients with advanced NSCLC, due to significant toxicity such treatment should be applied only in patients in good performance status. The introduction of targeted therapy, based on the molecular profile of the patient has allowed the management to be personalized, which may result in more effective treatment and may be safer for the patient.
Get Citation

Keywords

non-small cell lung cancer; chemotherapy; personalized therapy

About this article
Title

Treatment of non-small cell lung cancer — where we are?

Journal

Advances in Respiratory Medicine

Issue

Vol 81, No 1 (2013)

Pages

55-62

Published online

2012-12-13

Bibliographic record

Pneumonol Alergol Pol 2013;81(1):55-62.

Keywords

non-small cell lung cancer
chemotherapy
personalized therapy

Authors

Janusz Milanowski
Katarzyna Szmygin-Milanowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl